Source: MarketScreener

Jazz Pharmaceuticals, Inc: Jazz Pharmaceuticals : National Comprehensive Cancer Network adds Zepzelca (lurbinectedin) to Clinical Practice Guidelines in Oncology

(marketscreener.com) DUBLIN, July 13, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that Zepzelca was added by the National Comprehensive Cancer Network to the Clinical Practice Guidelines in Oncology for small cell lung cancer on July 7, 2020. The U.S. Food and Drug Administration approved Zepzelca under accelerated approval on...https://www.marketscreener.com/JAZZ-PHARMACEUTICALS-PLC-9829261/news/Jazz-Pharmaceuticals-National-Comprehensive-Cancer-Network-adds-Zepzelca-trade-lurbinectedin-t-30915702/?utm_medium=RSS&utm_content=20200713

Read full article »
Est. Annual Revenue
<$1M
Agree?
Est. Employees
<10
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100